---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-000053"
form_type: "8-K/A"
ticker: "PAHC"
cik: "0001069899"
company_name: "PHIBRO ANIMAL HEALTH CORP"
filed_at: "2025-01-07T23:59:59+00:00"
generated_at: "2026-05-28T07:44:24.143932+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Phibro discloses Zoetis MFA portfolio audited financials: $407.6M revenue in FY2023

## Summary
- Acquired MFA portfolio had $407.6M revenue & $91.2M revenue less direct expenses in 2023; up from $59.9M in 2022.
- Cost of sales was $284.3M in 2023 vs $310.3M in 2022; gross margin improved to 30.3% from 23.9%.
- Total assets acquired as of Dec 2023: $334M; liabilities assumed: $24.5M; net assets ~$309.5M.
- Transaction closed Oct 31, 2024 for $350M subject to adjustments; includes six manufacturing plants.
- Pro forma financials filed for year ended June 30, 2024; combined entity impact not yet quantified.

## SEC filing metadata
- accession: 0001558370-25-000053
- form_type: 8-K/A
- ticker: PAHC
- cik: 0001069899
- company_name: PHIBRO ANIMAL HEALTH CORP
- filed_at: 2025-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069899/000155837025000053/0001558370-25-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069899/000155837025000053/pahc-20241031x8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-000053
- JSON: https://secwatch.observer/filing/0001558370-25-000053.json
- Plain text: https://secwatch.observer/filing/0001558370-25-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.